A randomized Phase II study comparing SOX+B-mab with SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with KRAS wild type.
Ontology highlight
ABSTRACT: Interventions: A group (SOX+B-mab) TS-1 administered for 14 days followed by 7 days rest according to body surface area. L-OHP is administered intravenously in 130 mg/m2 at day 1. B-mab is administered intravenously in 7.5 mg/kg by tri-weekly.
B group (SOX+C-mab) TS-1 administered for 14 days followed by 7 days rest according to body surface area. L-OHP is administered intravenously in 130 mg/m2 at day 1. C-mab is administered intravenously in 400 mg/m2 on day 1, then 250 mg/m2 weekly thereafter. Or C-mab is administered intravenously in 500 mg/m2 by bi-weekly.
Primary outcome(s): Response rate
Study Design: Parallel Randomized
DISEASE(S): Previously Untreated Recurrent Advanced Colorectal Cancer With Kras Wild Type
PROVIDER: 2622133 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA